← All trials
NCT02047214
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2014
- Primary completion
- Dec 1, 2015
- Completion date
- Dec 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 17
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Cortice Biosciences, Inc.Lead sponsor
- University of RochesterOverall official - principal investigator
- Northwestern UniversityOverall official - principal investigator
- University of South FloridaOverall official - principal investigator
- Ohio State UniversityOverall official - principal investigator
- University of VirginiaOverall official - principal investigator
- Dartmouth UniversityOverall official - principal investigator
- Rutgers UniversityOverall official - principal investigator
- Washington University in St. LouisOverall official - principal investigator
- Memorial Hermann Health SystemOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- University of Alabama, BirminghamOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.